Phase1, Placebo-Controlled, Randomized, Double-blind, Single-ascending Dose Study in Healthy Subjects.
Completed
SolAeroMed Inc.
Phase 1
2014-03-01
To evaluate the safety and tolerability of S-1226 composed of perflubron with ascending doses
of carbon dioxide (4%, 8%, and 12% CO2) administered over 2 minute nebulisation to healthy
subjects.
ADAGP Charitable Foundation dba Auto Dealers CARing for Kids Foundation
Phase 1
2017-06-27
The primary study objective is to assess the safety and feasibility of perfluorooctylbromide
(PFOB) partial liquid ventilation (PLV) in infants with severe Bronchopulmonary Dysplasia
(BPD).
The primary study objective is to assess the safety and feasibility of perfluorooctylbromide
(PFOB) partial liquid ventilation (PLV) in infants with severe Bronchopulmonary Dysplasia
(BPD).
The primary study objective is to assess the safety and feasibility of perfluorooctylbromide
(PFOB) partial liquid ventilation (PLV) in infants with severe Bronchopulmonary Dysplasia
(BPD).
Safety, Tolerability and Efficacy Of S-1226 in Moderate Severity Covid-19 Bronchiolitis/Pneumonia
Suspended
SolAeroMed Inc.
Phase 2
2021-09-15
This is a randomized, open-label, controlled, Phase II proof of concept study to evaluate the
safety, tolerability and efficacy of S-1226 in which hospitalized subjects (n≤30) with
moderate severity COVID-19 Bronchiolitis/Pneumonia will be enrolled. The safety and
tolerability of S-1226 composed of PFOB with ascending doses of carbon dioxide (4%, 8%, and
12% CO2) administered twice daily will be assessed subjects in hospitalized subjects with
moderate severity COVID-19 Bronchiolitis/Pneumonia.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
